The University of Chicago Header Logo

David Grinblatt

Concepts (184)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Myelodysplastic Syndromes
7
2023
346
1.260
Why?
Registries
8
2023
703
0.920
Why?
Drug Industry
1
2023
54
0.880
Why?
Leukemia, Lymphocytic, Chronic, B-Cell
5
2020
136
0.690
Why?
Azacitidine
2
2017
137
0.620
Why?
Hematopoietic Stem Cell Transplantation
9
2023
878
0.400
Why?
Topotecan
2
2009
45
0.400
Why?
Antineoplastic Combined Chemotherapy Protocols
11
2022
2438
0.360
Why?
Prospective Studies
10
2023
4212
0.350
Why?
Blood Coagulation Factor Inhibitors
1
2008
4
0.340
Why?
Blood Coagulation Disorders
1
2008
63
0.310
Why?
Antimetabolites, Antineoplastic
2
2017
236
0.250
Why?
Leukemia, Myeloid, Acute
2
2023
763
0.240
Why?
Pathology, Molecular
1
2023
34
0.230
Why?
Laboratories
1
2023
43
0.230
Why?
Rituximab
3
2020
116
0.210
Why?
Aged, 80 and over
9
2020
6511
0.210
Why?
Lymphoma, Non-Hodgkin
4
2010
261
0.200
Why?
Erythroblasts
1
2020
25
0.190
Why?
RNA Splicing Factors
1
2020
27
0.190
Why?
Aged
16
2023
18407
0.190
Why?
Thrombocytopenia
2
2020
183
0.180
Why?
Pharmaceutical Preparations
1
2020
92
0.170
Why?
Phosphoproteins
1
2020
255
0.170
Why?
Humans
32
2023
86656
0.170
Why?
Middle Aged
21
2022
25027
0.170
Why?
Multiple Myeloma
1
2022
307
0.160
Why?
Adult
21
2020
25648
0.160
Why?
Hematopoietic Stem Cells
4
2009
292
0.160
Why?
Cytogenetics
1
2017
27
0.160
Why?
In Situ Hybridization, Fluorescence
1
2017
349
0.150
Why?
Vidarabine
1
2017
141
0.140
Why?
Treatment Outcome
7
2023
7982
0.140
Why?
Female
23
2022
44566
0.140
Why?
Antigens, CD34
5
2009
158
0.130
Why?
Male
18
2022
40995
0.130
Why?
Cyclophosphamide
4
2000
299
0.130
Why?
Hematologic Neoplasms
2
2009
329
0.120
Why?
Bone Marrow Transplantation
3
2002
286
0.110
Why?
Hematopoietic Stem Cell Mobilization
3
2010
50
0.110
Why?
Quality of Life
3
2016
1587
0.110
Why?
Leucovorin
1
1992
218
0.100
Why?
United States
4
2020
6674
0.100
Why?
Fluorouracil
2
1998
556
0.100
Why?
Salvage Therapy
2
2010
233
0.100
Why?
Hodgkin Disease
2
2010
177
0.090
Why?
Thiotepa
3
2000
32
0.090
Why?
Granulocyte-Macrophage Colony-Stimulating Factor
1
2010
112
0.090
Why?
Drug Administration Schedule
2
2009
915
0.090
Why?
Administration, Oral
2
2009
683
0.090
Why?
Blood Coagulation Tests
1
2008
35
0.080
Why?
Adenocarcinoma
2
1995
1169
0.080
Why?
Breast Neoplasms
5
2001
2904
0.080
Why?
Paclitaxel
2
2001
460
0.080
Why?
Thalidomide
1
2008
54
0.080
Why?
Follow-Up Studies
1
2014
3639
0.070
Why?
Young Adult
5
2020
5977
0.070
Why?
Prognosis
4
2017
3681
0.070
Why?
Granulocyte Colony-Stimulating Factor
4
2001
165
0.070
Why?
Pancreatic Neoplasms
1
1992
645
0.070
Why?
Purpura, Thrombocytopenic, Idiopathic
1
2006
12
0.070
Why?
Guillain-Barre Syndrome
1
2006
16
0.070
Why?
Leukocyte Count
4
2001
220
0.070
Why?
Risk Factors
2
2014
5416
0.070
Why?
Leukapheresis
3
2001
19
0.070
Why?
Immunoglobulins, Intravenous
1
2006
66
0.070
Why?
Stem Cell Transplantation
1
2006
183
0.060
Why?
Transplantation Conditioning
2
2009
373
0.060
Why?
Body Weight
1
2006
458
0.060
Why?
Immunologic Factors
1
2006
170
0.060
Why?
Survival Rate
6
2010
1864
0.060
Why?
Patient Compliance
1
2005
228
0.060
Why?
Remission Induction
3
2017
722
0.060
Why?
Transplantation, Homologous
4
2009
996
0.060
Why?
Imides
1
2022
26
0.050
Why?
Immunosuppressive Agents
1
2008
977
0.050
Why?
Proteasome Inhibitors
1
2022
51
0.050
Why?
Transplantation, Autologous
4
2010
331
0.050
Why?
Neoplasm, Residual
1
2022
162
0.050
Why?
Platelet Count
2
1999
92
0.050
Why?
Antineoplastic Agents, Alkylating
2
2000
138
0.050
Why?
Combined Modality Therapy
5
2010
1686
0.050
Why?
Dexamethasone
1
2022
326
0.050
Why?
Pilot Projects
1
2023
840
0.050
Why?
Taxoids
1
2001
129
0.050
Why?
Trastuzumab
1
2020
68
0.050
Why?
Antineoplastic Agents, Phytogenic
2
2001
276
0.050
Why?
Iron
1
2020
164
0.050
Why?
Silicon Dioxide
1
2000
39
0.040
Why?
Health Services Accessibility
1
2023
394
0.040
Why?
Antibodies
1
2020
352
0.040
Why?
Disease-Free Survival
3
2008
1204
0.040
Why?
Genomics
1
2023
720
0.040
Why?
Cell Count
2
2009
197
0.040
Why?
Immunoglobulin Heavy Chains
1
2017
131
0.040
Why?
Immunoglobulin Variable Region
1
2017
109
0.040
Why?
Recurrence
3
2008
1139
0.040
Why?
Lymphoma
1
1999
262
0.040
Why?
Chromosome Deletion
1
2017
229
0.040
Why?
Antibodies, Monoclonal, Humanized
1
2022
931
0.040
Why?
Antineoplastic Agents
2
2005
2360
0.030
Why?
Sample Size
1
2016
130
0.030
Why?
Hematopoietic Cell Growth Factors
1
1995
11
0.030
Why?
Age Factors
2
2013
1849
0.030
Why?
Kaplan-Meier Estimate
1
2017
861
0.030
Why?
Chromosome Aberrations
1
2016
387
0.030
Why?
Carcinoma
1
1998
436
0.030
Why?
Ovarian Neoplasms
1
2001
744
0.030
Why?
Disease Management
1
2016
328
0.030
Why?
Interleukin-6
1
1995
257
0.030
Why?
Melphalan
1
1994
98
0.030
Why?
Recombinant Proteins
3
2001
1018
0.030
Why?
Fatigue
1
2013
175
0.030
Why?
Practice Patterns, Physicians'
1
2016
584
0.020
Why?
Filgrastim
2
2001
56
0.020
Why?
Neoplasm Staging
2
2010
1938
0.020
Why?
Antibodies, Monoclonal, Murine-Derived
1
2010
78
0.020
Why?
Immunomodulation
1
2010
55
0.020
Why?
Sex Factors
1
2013
1053
0.020
Why?
Longitudinal Studies
1
2013
1019
0.020
Why?
Interleukin-2
1
2010
250
0.020
Why?
Calibration
1
2009
99
0.020
Why?
Mutation
1
2020
3977
0.020
Why?
Depression
1
2013
472
0.020
Why?
Submitochondrial Particles
1
1987
3
0.020
Why?
Mitochondria, Liver
1
1987
27
0.020
Why?
Drug Therapy, Combination
1
2010
895
0.020
Why?
Retrospective Studies
3
2009
8476
0.020
Why?
Neurotoxins
1
1987
49
0.020
Why?
Treatment Failure
1
2008
286
0.020
Why?
Neutropenia
2
2001
215
0.020
Why?
Thromboembolism
1
2008
119
0.020
Why?
Oxygen Consumption
1
1987
239
0.020
Why?
Carcinoma, Squamous Cell
1
1994
1077
0.020
Why?
Drug Resistance, Neoplasm
1
2010
592
0.020
Why?
Head and Neck Neoplasms
1
1994
1052
0.020
Why?
Neutrophils
2
2000
308
0.020
Why?
Thinness
1
2006
43
0.020
Why?
Siblings
1
2006
111
0.020
Why?
Pyridines
1
1987
310
0.020
Why?
Tissue and Organ Harvesting
1
2006
79
0.020
Why?
Overweight
1
2006
118
0.020
Why?
Immunotherapy
1
2010
631
0.020
Why?
Antigens, CD
1
2006
459
0.010
Why?
Analysis of Variance
1
2006
911
0.010
Why?
Antibodies, Monoclonal
1
2010
1380
0.010
Why?
Graft vs Host Disease
1
2006
365
0.010
Why?
Graft Survival
1
2006
885
0.010
Why?
Survival Analysis
1
2006
1540
0.010
Why?
Antineoplastic Protocols
1
2002
9
0.010
Why?
Colloids
1
2000
25
0.010
Why?
Blood Platelets
1
2000
149
0.010
Why?
Carboplatin
1
2000
286
0.010
Why?
Stomatitis
1
1998
30
0.010
Why?
Adolescent
2
2006
8988
0.010
Why?
Evaluation Studies as Topic
1
1999
274
0.010
Why?
Esophagitis
1
1998
43
0.010
Why?
Stem Cells
1
2001
358
0.010
Why?
Pulmonary Alveoli
1
1998
71
0.010
Why?
Vincristine
1
1998
111
0.010
Why?
Infusions, Intravenous
1
1998
429
0.010
Why?
Mitoxantrone
1
1998
68
0.010
Why?
Randomized Controlled Trials as Topic
1
2002
864
0.010
Why?
Diarrhea
1
1998
182
0.010
Why?
Brain Diseases
1
1998
180
0.010
Why?
Methotrexate
1
1998
249
0.010
Why?
Doxorubicin
1
1998
295
0.010
Why?
Hemorrhage
1
1998
267
0.010
Why?
Clinical Trials as Topic
1
2002
1169
0.010
Why?
Lung Diseases
1
1998
263
0.010
Why?
Hyperbilirubinemia
1
1995
20
0.010
Why?
Life Tables
1
1995
48
0.010
Why?
Cisplatin
1
1998
612
0.010
Why?
Sensitivity and Specificity
1
1999
1991
0.010
Why?
Incidence
1
1998
1578
0.010
Why?
Drug Evaluation
1
1994
141
0.010
Why?
Injections, Intravenous
1
1994
242
0.010
Why?
Bone Marrow
1
1994
435
0.010
Why?
Cohort Studies
1
1998
2765
0.010
Why?
Time Factors
1
1998
5215
0.010
Why?
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
1
1987
8
0.000
Why?
Structure-Activity Relationship
1
1987
408
0.000
Why?
Rats
1
1987
4004
0.000
Why?
Animals
1
1987
26706
0.000
Why?
Grinblatt's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (184)
Explore
_
Co-Authors (17)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_